$BTX In response to Seeking Alpha article "Brooklyn ImmunoTherapuetics up 66% on no news or catalysts," The INSPIRE Phase 2 clinical trial studying an IRX-2-based regimen for squamous cell carcinoma completed 3/2021 and should have pending results. SOURCE: clinicaltrials.gov/ct2/show... SCREENSHOT OF BOTH: